Indian Biologics Watch Canada, U.S. Treatments Of Follow-Ons
This article was originally published in PharmAsia News
Executive Summary
India's biologics industry expects the United States and Canada, acting separately, to propose regulations of biologics similar to the practice already underway in Europe. Canada has a guidance document available and expects its second guidance, on subsequent entry biologics, to be released in March. U.S. FDA also has drafted a proposed way of treating follow-on biologics, but that is still in the internal review process. Both Canada and the U.S. are expected to follow the European model. (Click here for more
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.